Market Overview

UPDATE: Citigroup Upgrades PAREXEL International to Buy on Operational Improvement, Valuation

Share:
Related PRXL
Deutsche Bank's Top 20 'Best Buy Ideas'
Top 4 NASDAQ Stocks In The Medical Laboratories & Research Industry With The Highest EPS

Citigroup raised its rating on PAREXEL International (NASDAQ: PRXL) from Neutral to Buy and increased its price target from $34 to $36.

Citigroup commented, "We are upgrading PRXL to Buy with a $36 price target (+$2) based on: a misunderstood press release issued December 27th to announce a modest acquisition that is favorable, improving core operational metrics & related read-through to its major big pharma partnership implementation, and recent pullback in valuation. We also note $100mn worth of remaining share repurchase authorization as the initial $100mn buyback concludes that may create a near term catalyst. Net, we believe the mix of positive data points together with a more palatable valuation creates a favorable risk/reward profile for investors."

PAREXEL International closed at $29.21 on Monday.

Latest Ratings for PRXL

DateFirmActionFromTo
Feb 2015CitigroupMaintainsBuy
Jan 2015Deutsche BankMaintainsHold
Jan 2015SunTrust Robinson HumphreyDowngradesBuyNeutral

View More Analyst Ratings for PRXL
View the Latest Analyst Ratings

Posted-In: CitigroupAnalyst Color Upgrades Pre-Market Outlook Analyst Ratings

 

Related Articles (PRXL)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Benzinga PRO content